IXICO

Introduction to **IXICO**

IXICO is a **specialist provider of neuroscience expertise and global operations** to deliver imaging and digital biomarker analytical services for clinical development.

We operate exclusively in the Neuroscience field, with an extensive track record in key disease areas including:

- › **Alzheimer's Disease**
- › **Huntington's Disease**
- › **Parkinson's Disease**
- › **Multiple Sclerosis**
- › **Progressive Supranuclear Palsy**
- › **Schizophrenia**
- › **Other Movement Disorders & Dementias**

2,000+
IXICO-qualified imaging sites

75+
Countries with trials deployed

"
Having their expertise was really important. Some companies just provide the results. In this case, we really needed their help in making sense of the data and they were there to help us and this was crucial. "

SPECIALIST BIOTECH, 2019

IXICO

Our extensive track record delivering end to end support in the development and deployment of imaging and digital biomarkers in clinical trials has driven our success and engagement within the neuroscience community. We have provided both PET and MRI biomarkers for over 70 clinical studies in neuroscience, of which, over 30 have been in Alzheimer's disease.

Innovation is at the heart of what we do at IXICO, with our R&D programs prioritised to deliver the most valuable imaging and digital data, and enhance the success of neurological treatments. Our deep neuroscience understanding combined with our AI data analytics expertise has enabled us to build a reputation as a trusted partner with our clients, key industry leaders and consortia.

We are there every step of the way to ensure the most valuable insights are extracted from imaging and digital data. Our innovative drive will continue to help our clients realise the potential of AI technology in drug development.

We deliver data analytics for:

STRATIFICATION & ENRICHMENT

DRUG DEVELOPMENT

POST MARKETING

End to End Clinical Support

CLINICAL PROGRAM DESIGN & CONSULTATION

Drawing on our neuroscience expertise and experience, we help you select the most optimal methods and leading-edge analysis to deliver the insights you need.

PROJECT MANAGEMENT

Our project management team ensures the efficient set-up and ongoing delivery of your studies. They work with you to gather your requirements, deliver documentation, and provide clear communication to all project stakeholders.

SITE SETUP & MANAGEMENT

Our site management and imaging science teams work together to design and deploy harmonised image acquisition protocols across sites. We provide interactive, comprehensive training, having qualified over 2,000 sites globally.

DATA MANAGEMENT & QUALITY CONTROL

Image and data quality is assessed through our digital platform, TrialTracker™, with both automated quality and visual assessments by our expert image analysts to ensure that it meets the study requirements.

READING & ANALYSIS

We provide a comprehensive suite of data analysis tools and neuroradiology reading workflows that can be tailored specifically to the study requirements, maximising the ability to capture study-specific data relating to the disease area, drug delivery mechanism, drug mode of action, as well as drug safety and efficacy.

REGULATORY PATHWAY

Our teams are experienced in deploying imaging and digital biomarkers within a regulatory compliant framework. Our scientists also collaborate at the forefront of developing the regulatory pathway for imaging and digital biomarkers as drug development tools. As new technologies emerge, we work with you to validate new biomarkers and endpoints and support interactions with regulators.

AI Technology & Digital Biomarkers

IXICO has been harnessing machine learning and AI since the company's inception in 2004 and has developed, validated and deployed innovative AI technology in clinical trials to improve the success of drug development within neuroscience.

One of our proprietary AI algorithms, LEAP, provides accurate assessment of changes in brain pathology through the quantification of regional brain volume. LEAP has been applied to over 150 brain regions and has been cited in more then 750 scientific publications.

We combine the rapid deployment of our AI algorithms with our bespoke TrialTracker™ data management platform to interpret large data sets of patient brain scans (MRI/PET), which has the potential to deliver lower costs, faster enrolment and higher statistical power in clinical trials.

We're working to develop interpretive algorithms to extract clinically meaningful biomarkers from new data types, such as from wearable biosensors. Sleep and movement are impacted in many CNS diseases. At IXICO, we are using wearable biosensors to passively capture data on sleep, movement, balance and activity, and are translating this data into new digital biomarkers using IXICO's AI technology. These biomarkers have the potential to provide more precise, patient-centric and clinically meaningful clinical trial endpoints compared to current research methods, such as subjective rating scales and patient diaries.

Imaging & Biomarker Analysis

We understand the complexities of operationalising brain imaging biomarkers in clinical development. By standardising the acquisition, collection and analysis of images, we deliver high quality and clinically meaningful data. IXICO's scientists also collaborate with academic and pharma partners to translate novel neuroimaging methods into clinical development programs and develop new image analysis algorithms that provide richer, more sensitive brain structural and functional information.

100,000+

Brain scans analysed

20,000+

Patient & Safety Reports Delivered

> IXICO is really a great service provider. Good quality, responsive, I don't think we could ask for more.

TOP 10 PHARMA, 2019

ELIGIBILITY / STRATIFICATION		SAFETY	EFFICACY			
Structural MRI	PET	Structural MRI	Structural MRI	PET	Advanced MRI	Actigraphy

IMAGING	BIOSENSOR